AIA Petition In Generic Zomig Case Is Time-Barred, PTAB Says
The Patent Trial and Appeal Board refused to review a patent on AstraZeneca AB's Zomig nasal spray Wednesday, ruling that a company that wants to make a generic version of the...To view the full article, register now.
Already a subscriber? Click here to view full article